KRAS and familial pancreatic carcinoma: This research proposes a dendrimer-based nanoradiopharmaceutical (177Lu-DN(C19)-CXCR4L) that encapsulates C19 and targets CXCR4 receptors, serving as both a targeted radiotherapy system using lutetium-177 and an oncotherapeutic agent by stabilizing the KRAS4b-PDE complex, thus offering a dual-specific therapy for pancreatic cancer.